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Genomic rearrangements are thought to occur pro-
gressively during tumor development. Recent find-
ings, however, suggest an alternative mechanism,
involving massive chromosome rearrangements in a
one-step catastrophic event termed chromothripsis.
We report the whole-genome sequencing-based
analysis of a Sonic-Hedgehog medulloblastoma
(SHH-MB) brain tumor from a patient with a germline
TP53 mutation (Li-Fraumeni syndrome), uncovering
massive, complex chromosome rearrangements.
Integrating TP53 status with microarray and deepsequencing-based DNA rearrangement data in
additional patients reveals a striking association
between TP53 mutation and chromothripsis in
SHH-MBs. Analysis of additional tumor entities
substantiates a link between TP53 mutation and
chromothripsis, and indicates a context-specific
role for p53 in catastrophic DNA rearrangements.
Among these, we observed a strong association
between somatic TP53 mutations and chromothrip-
sis in acutemyeloid leukemia. Thesefindingsconnect
p53 status and chromothripsis in specific tumor
types, providing a genetic basis for understanding
particularly aggressive subtypes of cancer.Cell 148, 59–71, January 20, 2012 ª2012 Elsevier Inc. 59
Table 1. Whole-Genome Sequencing and DNA Sequence Variant
Statistics
LFS-MB1 LFS-MB2 LFS-MB3 LFS-MB4
Tumor bases
sequenced
109 3 109 120 3 109 37 3 109 143 3 109
Paired normal
tissue bases
sequenced
116 3 109 125 3 109 17 3 109 114 3 109
Tumor physical
coverage
(span coverage)
43.5x 45.8x 77.8x 112.2x
Paired normal
physical coverage
41.6x 51.6x 3.3x 49.5x
Tumor sequencing
coverage
30.8x 34.6x 8.9x* 38.5x
Paired normal
sequencing
coverage
31.4x 36.7x 4.6x* 34.4x
Total somatic
mutations
(whole genome)
3,716 3,053 - 2,494
Nonsilent coding
mutations
(val./tested)
24 (20/21) 22 (19/20) 18(/)* 11 (8/10)
Mutation
rate per Mb
1.29 1.06 - 0.88
* In addition to whole-genome sequencing, whole-exome data was
generated at 39x (tumor) and 37x (paired normal) coverage in this case.
‘‘-,’’ not assessed; val., validated.INTRODUCTION
Li-Fraumeni syndrome (LFS, OMIM #151623) is an autosomal
dominant hereditary disorder that is associated with a greatly
increased susceptibility to cancer (Li and Fraumeni, 1969).
Most LFS patients harbor heterozygous germline mutations of
TP53, the gene encoding the p53 tumor suppressor (Malkin
et al., 1990). Mutant p53 can prime cells for tumor development
due to aberrant cell cycle control and DNA damage response
signals, and a failure to induce cell cycle arrest, senescence or
apoptosis (Forbes et al., 2011; Vogelstein et al., 2000).
In a pilot study within the International Cancer Genome
Consortium (ICGC) Pediatric Brain Tumor Research Project
(www.pedbraintumor.org) we analyzed a medulloblastoma and
paired normal sample from an LFS patient by whole-genome
sequencing. Medulloblastoma is the most common malignant
brain tumor of childhood, and themalignancy causing the highest
cancer-relatedmortality in children.Medulloblastoma belongs to
the spectrum of recognized LFS tumors (Taylor et al., 2000).
Recent molecular studies have revealed that medulloblastoma
comprises at least four distinct sub-entities, which differ in terms
of cell-of-origin, clinicopathologic features, anddiseaseoutcome
(Cho et al., 2011; Gibson et al., 2010; Kool et al., 2008; Northcott
et al., 2011b; Remke et al., 2011). The investigated patient had
aSonic-Hedgehogsubtypemedulloblastoma (SHH-MB),a tumor
arising from the external granular layer cells of the cerebellum
(Bu¨hren et al., 2000; Wechsler-Reya and Scott, 1999). SHH-
MBs form the clinically and histopathologically most heteroge-
neousmedulloblastomasubtype,making it challenging topredict
response to therapy and patient outcome solely based on
subtype affiliation (Northcott et al., 2011a; Remke et al., 2011).
Cancer genome sequencing efforts underway will likely enable
further refinements in medulloblastoma subtype classification,
and provide novel molecular signatures for patient stratification.
Unexpectedly, the tumor genomeshowedmassive genomic re-
arrangementsconsistentwitha reshufflingofgeneticmaterial from
individual chromosomes, in keeping with the recently proposed
chromothripsis model for tumorigenesis (Greek; chromo from
chromosome; thripsis, for shattering into pieces; Stephens et al.,
2011). Chromothripsis, which is thought to occur in 2%–3% of
cancers (with an incidence of 25% in bone cancers; Stephens
et al., 2011), involves the acquisition of numerous rearrangements
through a single catastrophic event, fundamentally different from
the stepwise (progressive) acquisition of alterations by tumor cells
(Fearon andVogelstein, 1990;Nowell, 1976). In this study,we inte-
grate whole genome sequencing and array-based approaches to
further characterize this rearrangement phenomenon, and
discoveranovel linkbetweenchromothripsis andTP53mutations,
providing evidence that the status of p53 can influence cata-
strophic DNA rearrangements in a cell context-specific manner.
RESULTS
Whole-Genome Sequencing of a Medulloblastoma
in a Li-Fraumeni Syndrome Patient Revealed Highly
Complex DNA Rearrangements
We initially analyzed an SHH-MB and paired normal tissue
sample from a female LFS patient (LFS-MB1), who harbored60 Cell 148, 59–71, January 20, 2012 ª2012 Elsevier Inc.a hereditary TP53mutation (Table S1 available online) predicted
to eliminate p53 DNA binding activity (Rieber et al., 2009). We
performed whole-genome paired-end sequencing followed by
DNA sequence variant discovery (Table 1). We searched for
single nucleotide variants (SNVs) by directly evaluating the align-
ment of DNA reads onto the human reference genome (Depristo
et al., 2011; Li et al., 2009) and identified large-scale rearrange-
ments by paired-end mapping (Korbel et al., 2007), split-read
analysis (Ye et al., 2009), and read-depth analysis (Abyzov
et al., 2011; Chiang et al., 2009; Waszak et al., 2010).
The inherited TP53 mutation was detected in both tissue
samples. Furthermore, we identified 24 tumor-specific SNVs
that were predicted to alter protein-coding sequences (Table 1,
Table S1, and Figure 1A). This is slightly more than was observed
in a recent study focusing on exonic regions in sporadic medul-
loblastomas (average 5.7 nonsynonymous SNVs per sample;
range 1–17 [Parsons et al., 2011]). These differences could
reflect an increased genome-wide mutation rate in LFS patients
or could be the result of a comparably higher sensitivity of our
whole-genome sequencing approach. Using PCR we verified
20 out of 21 SNVs for which PCR primers could be designed
(>95%). We did not observe any somatic small insertions or
deletions (<50 bp) in protein-coding regions. However, we
uncovered numerous large (up to megabase-scale) alterations
in the tumor sample. Among these were distinct amplifications
of SHH pathway members (MYCN and GLI2), which we verified
by fluorescence in situ hybridization (FISH), and a somatic loss
Figure 1. Analysis of LFS-MB1 Revealed Catastrophic DNA Rearrangements Consistent with Chromothripsis
(A) Genome-wide distribution of somatic DNA variants. Thin orange lines in outer-most panel are nonsynonymous somatic SNVs; the next panel shows isolated
genomic rearrangements. Read-depth plots (log2-ratio tumor versus germline), indicating copy-number alterations, are in black. Connecting lines show complex
large-scale (e.g., interchromosomal) rearrangements identified by paired-end mapping.
(B) Inferred double-minute chromosome structure (originating segments from chromosome 4 and 14 are highlighted in panel [A]). Genes are in gray (known cancer
genes are in red).
(C) PCR validation of interchromosomal rearrangements contributing to the inferred double-minute chromosome. MB, medulloblastoma; GL, germline.
(D) FISH validation of rearrangements contributing to double-minute chromosome derived from chromosome 3 segments. Probes match to normally distal
regions of chromosome 3 (RP11-553D4, red, and RP11-265F19, green; see panel [A] and Figure S1).
(E) Amplification ofMYCN (red) and GLI2 (green), not associated with chromothripsis (amplicon loci highlighted in panel [A] with red and light green boxes), was
observed in distinct subpopulations of cells.of the wild-type TP53 allele by deletion of the 17p chromosome
arm (Table S1, Figure 1E).
The most striking feature in LFS-MB1, however, was a pattern
of complex somatic rearrangements that was markedly different
from aberrations that we, and others have previously described
in medulloblastoma (Cho et al., 2011; Northcott et al., 2009; Pfis-
ter et al., 2009). This included multiple highly amplified genomic
segments, which were clustered on individual chromosome
arms (Figure 1A), resulting in frequent alternations between a
normal disomic copy-number state and an extreme state with
a segmental copy-number of up to 30. On chromosome 3, three
segments were highly amplified, whereas on chromosome 4,
six segments were amplified and on chromosome 14, foursegments were amplified. Based on the mapping of sequenced
paired-ends, we determined physical connections linking the
amplified sequences on chromosome 3 (intrachromosomal), as
well as the amplified segments from chromosomes 4 and 14
(interchromosomal). Strikingly, the amplified fragments from
chromosomes 4 and 14 appeared fused together to form
a circular 1.2Mb extra-chromosomal structure (so-called
‘‘double-minute’’ chromosome) consisting of a complex medley
of inter- and intrachromosomal junctions (Figure 1B). Using
PCR, we verified a series of these connections, including all
four interchromosomal links (Figure 1C, Table S1). FISH experi-
ments also confirmed the predicted colocalization of highly
amplified segments on chromosome 3, indicating that theseCell 148, 59–71, January 20, 2012 ª2012 Elsevier Inc. 61
Figure 2. SNP Array Copy-Number Profiles Reveal
a Link between TP53Mutation and Chromothripsis
in SHH-MB
(A) Maximum number of copy-number state changes, and
amplicon counts, on most strongly affected (rearranged)
chromosomes. Abbreviation: hemiz., hemizygous. Further
details are available as Data S1. Random noise was added
(i.e., addition, or subtraction, of < 0.5 copies) for visuali-
zation purposes.
(B) Boxplot with maximum copy-number state changes on
most strongly affected chromosome for different tumor
subtypes and TP53 statuses. *An outlying point observed
in LFS-MB3 (>200 copy-number state changes) was
omitted for visualization purposes.fragments formed yet another double-minute chromosome
(Figure 1D, Figure S1), as predicted by the sequencing data.
It is unlikely that these extrachromosomal structures occurred
as a consequence of progressive genomic alterations. Double-
minute chromosomes have been described to typically encom-
pass segments from confined genomic regions, rather than
from several distinct regions of a chromosome or multiple
chromosomes (Storlazzi et al., 2010). The recently described
chromothripsis phenomenon, however, may explain the ob-
served complex rearrangements, as this phenomenon can lead
to the formation of double-minute chromosomes containing
fragments from multiple regions (Stephens et al., 2011). The
chromothripsis model can further explain the strikingly similar,
alternating copy-number states of adjacent amplicons and the
medley of relative orientations with which DNA fragments
rearranged.
DNA Copy-Number Profiling of Additional
Medulloblastomas Reveals a Link between TP53
Mutations and Chromothripsis in SHH-MB
Previous studies have shown that evidence for chromothripsis
can be inferred from SNP microarray-based DNA copy-number62 Cell 148, 59–71, January 20, 2012 ª2012 Elsevier Inc.profiles (Stephens et al., 2011). To assess the
occurrence of chromothripsis in a broader
series, we analyzed SNP array data from 98
medulloblastomas, including samples from all
four molecular subtypes (Table S2). We also
carried out TP53 sequencing in all tumors.
Specifically, we analyzed 73 sampleswith previ-
ously published SNP array data (Northcott et al.,
2009), and generated additional SNP array data
for 25 tumors, including nine with known TP53
mutations. To infer the occurrence of chromo-
thripsis, we required at least 10 changes in
segmental copy-number involving two or three
distinct copy-number states on a single chro-
mosome (see Experimental Procedures).
The vast majority of tumors displayed con-
siderably fewer than ten copy-number state
changes per chromosome (Figure 2, Data S1).
A subset of cases, however (13/98), showed
rearrangements consistent with chromothripsis
(Figure 2, Data S1). Notably, eleven of thesethirteen cases were SHH-MBs, and ten out of the eleven SHH-
MBs harbored TP53 mutations, whereas three cases (including
one SHH-MB and two Group 4 subtype medulloblastomas)
displayed a single copy TP53-loss through hemizygous 17p
deletion (Figure 2). Strikingly, all (10/10) SHH-MBs with mutant
TP53 displayed rearrangements consistent with chromothripsis,
whereas none (0/22) of the wild-type (TP53+/+) SHH-MBs
showed evidence for chromothripsis (Figure 2, Data S1). This
difference is highly significant (p = 1.63 108, two-tailed Fisher’s
exact test), indicating that mutant TP53 is strongly associated
with chromothripsis in SHH-MB.
The ten mutant TP53 tumors with chromothripsis included
two cases with heterozygous TP53 mutation (TP53+/m) and
eight cases with loss of the wild-type TP53 allele (TP53m/-). By
comparison, only one of three SHH-MBs in our cohort harboring
a TP53+/ genotype (hemizygous 17p deletion) showed rear-
rangements consistent with chromothripsis. Whereas TP53
mutation can impair or reduce the function of p53 due to domi-
nant negative activity, hemizygous TP53 deletion may not have
as significant an effect on protein function, since p53 expression
levels are primarily regulated post-translationally (reviewed in
Vogelstein et al., 2000).
The other three medulloblastoma subtypes rarely or never
displayed rearrangements consistent with chromothripsis. In
the Group 4 medulloblastoma subtype, 2/26 cases showed a
copy-number pattern consistent with chromothripsis (both in
the context of hemizygous TP53 deletion). In the Group 3
subtype, we did not observe evidence for chromothripsis among
26analyzed tumors (Figures 2Aand2B).NoTP53mutationswere
observed in either Group 3 or Group 4 tumors. WNT subtype
tumors also did not display any evidence for chromothripsis (0/
11), despite the known association of TP53 mutations with this
subgroup (Pfaff et al., 2010) and 4/11 cases harboring a TP53
mutation. These results indicate that the link between p53 status
and chromothripsis in medulloblastoma is context-specific.
The inferred association between TP53 and chromothripsis in
SHH-MB makes it tempting to hypothesize that these cata-
strophic DNA rearrangements may have occurred as a conse-
quence of preceding TP53mutations. To examine whether other
medulloblastoma patients with chromothripsis harbored germ-
line mutations, we analyzed constitutional DNA samples for
those TP53mutant cases where paired normal tissue was avail-
able. We were able to retrieve germline DNA for 3 of the 4 TP53
mutated WNT tumors, and 6/10 TP53 mutated SHH tumors.
Strikingly, whereas the TP53 mutations in the WNT group were
all somatically acquired (3/3), most of the tested germline
samples from the SHH group (5/6) harbored the same TP53
alterations as their paired tumors. Thus, in addition to linking
p53 status to complex chromosomal rearrangements, we also
identified five previously undiagnosed LFS cases among the
SHH-MBs showing chromothripsis, which we herein refer to as
LFS-MB2–LFS-MB6 (Table S2).
We used deep sequencing, followed by counting DNA reads
that identify mutant or wild-type TP53 alleles, to analyze the
abundance of mutant TP53 relative to wild-type TP53 in several
tumors. This analysis followed the rationale that a high mutant
allele frequency can indicate an early mutational event, whereas
a low frequency indicates late occurrence—an analysis that may
facilitate an evaluation of cause versus consequence. We used
this approach in four SHH-MBs with germline TP53 mutation
(LFS-MB1–LFS-MB4), the single SHH-MB with confirmed
somatic TP53 mutation and chromothripsis (MB2034), and two
TP53 mutated WNT medulloblastomas (Extended Experimental
Procedures). The mutant allele frequencies of the LFS-associ-
ated SHH-MBs were 87%–100% (Table S2), suggesting that
loss of the wild-type TP53 allele is typically an early event in
SHH-MBs seen in LFS patients. Whereas the WNT subtype
medulloblastomas showed comparably lower mutant TP53
allele frequencies (35%–48%), all (14/14; 100%) DNA reads of
the SHH-MB tumor MB2034 mapped to the mutant TP53 allele.
Absence, or very low frequency, of the TP53 wild-type allele
suggests that the somatic TP53 mutation likely occurred as
a very early (possibly initiating) event during medulloblastoma
tumorigenesis in MB2034.
DNA Copy-Number Profiles of Medulloblastoma Mouse
Models Substantiates the Link between TP53 and
Chromothripsis in SHH-MB
We further reanalyzed published microarray data from two
SHH-MB mouse models. The mice were hemizygous forpatched (Ptch+/), which promotes the development of SHH-
MB-like tumors (Buonamici et al., 2010; Ishida et al., 2010).
One study examined tumor growth in mice receiving medullo-
blastoma tumors (allografts) from a donor mouse lacking the
murine p53 ortholog (Trp53) and a copy of patched (Buonamici
et al., 2010) whereas another study examined tumors from
Ptch+/;Trp53+/+ mice (Ishida et al., 2010). All six tumors in
mice receiving allografts from the Ptch+/;Trp53/ donor
showed rearrangements consistent with chromothripsis (Data
S2). Chromosome 16 was affected in each case, suggesting
that chromothripsis had occurred already in the donor. 2/6 recip-
ient mice further acquired alterations consistent with chromo-
thripsis on other chromosomes (Extended Experimental Proce-
dures). By comparison, none (0/3) of the Ptch+/;Trp53+/+
mice showed chromothripsis (Data S2). These findings provide
additional support for a link between chromothripsis and p53
in SHH-MB.
Whole-Genome Sequencing of Three Additional
TP53 Mutated SHH-MBs Verifies the Occurrence
of Chromothripsis
We next subjected SHH-MB and paired normal tissue samples
from three of the newly identified LFS patients (LFS-MB2–LFS-
MB4) to additional analysis by whole-genome sequencing,
using the same approach as with LFS-MB1. One case (LFS-
MB3) was sequenced to a lower whole-genome coverage
(Table 1) sufficient for confirming the presence of chromothrip-
sis, complemented by deep sequencing of exonic regions using
a targeted exome capture approach. To better facilitate a
detailed characterization of the massive rearrangements seen
in chromothripsis, we additionally used long-range paired-end
mapping (Korbel et al., 2007), generating deep physical
genomic coverage of the two samples for which sufficient
DNA was available (Table 1).
We identified 11–24 nonsynonymous somatic SNVs in the
three tumor samples (Table 1, Table S3, Table S4)—again higher
than the rate previously reported in sporadic medulloblastoma
(Parsons et al., 2011). The only recurrently altered gene we
identified was TP53, which was confirmed to be mutated in the
germline in all cases. Importantly, the genome sequencing
data further verified the SNP array-based inference of chromo-
thripsis in all tumors. Specifically, LFS-MB2 showed chromo-
thripsis on chromosomes 3 and X, with resulting amplicons
that were physically connected to form a complex double-
minute chromosome (Figures 3A and 3B). Furthermore, chromo-
somes 8 and 17 displayed multiple alternations between few
copy-number states, involving a crisscrossing between one,
two and three copies (Figure 3A)—a rearrangement pattern
that is also typical for chromothripsis (Stephens et al., 2011). In
LFS-MB3, chromosome 15 displayed one of the most striking
genomic alteration patterns in our sample set, with > 100
highly-rearranged segments (Figure 3D). LFS-MB4 showed rear-
rangements consistent with chromothripsis on chromosomes
2 and 12, with several of the chromosome 2 segments forming
another double-minute chromosome (Figures 4A and 4B).
We performed experimental validations overall 27 PCRs and 3
FISH experiments, on all four SHH-MBs in which we carried out
whole-genome sequencing. These experiments verified theCell 148, 59–71, January 20, 2012 ª2012 Elsevier Inc. 63
Figure 3. Verification of Chromothripsis in LFS-MB2 and LFS-MB3 by Whole-Genome Sequencing
(A) Copy-number profiles in LFS-MB2.
(B) Predicted double-minute chromosome structure. *Segments connected to centromere-like repeat sequences.
(C) FISH confirming colocalization of fragments from chromosomes 3 and X in LFS-MB2 (RP11-245A6, green and CTD-2530H13, red); positions of FISH probes
are shown on the inner-most circle of panel [B]). PCR experiments also confirmed this colocalization (see Figure S2).
(D) Read-depth plot showing chromosome 15 rearrangements resulting from chromothripsis in LFS-MB3. Links connecting amplified regions are displayed on
top (other links involving rearranged segments are displayed at the bottom).chromothripsis-associated rearrangements inferred by paired-
end mapping (Figure 1, Figure 3, Figure 4, Figure S2). The FISH
experiments further confirmed the presence of double-minute
chromosomes in nearly all tumor cells. In conjunction with the
high magnitude of log-ratio shifts in the context of single-copy
alterations resulting from chromothripsis (Figures 3A and 3D,
Figure 4A, Data S1), this finding indicates an early occurrence
of chromothripsis in SHH-MB tumorigenesis rather than a later,
sub-clonal event.
Known Medulloblastoma Oncogenes Are Frequently
Amplified as a Result of Chromothripsis
Given the high incidence of chromothripsis in LFS-associated
SHH-MB, we speculated that this phenomenon is a key driver64 Cell 148, 59–71, January 20, 2012 ª2012 Elsevier Inc.of SHH-MB tumorigenesis. We observed an enrichment of
oncogenes (2.3-fold enrichment; p < 0.03; Fisher’s exact test),
and more specifically of oncogenes involved in SHH signaling
(30-fold enrichment; p < 0.0002; see Table 2), among highly
amplified segments rearranged by chromothripsis. The abun-
dance of oncogenes likely explains the observed high copy-
numbers of rearranged structures such as double-minute
chromosomes—presumably resulting from unequal segregation
during cell division and subsequent selection for a growth advan-
tage of malignant cells.
Notably, in LFS-MB4 the chromothripsis-associated rear-
rangements brought two SHH signaling genes on chromosome
2, i.e., MYCN and GLI2, into close proximity (Figure 4). This
pattern is in contrast to LFS-MB1, where the SHH-MB
Figure 4. Verification of Chromothripsis in LFS-MB4
(A) DNA copy-number profiles.
(B) Inferred double-minute chromosome structure with SHH pathway members MYCN and GLI2.
(C) PCR confirms juxtaposition of segments shown in panel (B).
(D) FISH verifying colocalization of MYCN (red) and GLI2 (green).oncogenesMYCN andGLI2were amplified in different tumor cell
subpopulations, and where chromosome 2 was not affected
by chromothripsis (Figure 1). Furthermore, in LFS-MB1 we
observed another SHH signaling gene,BOC, amplified in associ-
ation with chromothripsis (Table 2 and Figure S1).
In two patients, the chromothripsis-associated rearrange-
ments led to the formation of putative in-frame fusions involving
genes previously reported to be dysregulated in cancer (Table 2,
Figure 4B). One of these genes, NEB, was recently reported to
harbor somatic point mutations in medulloblastoma (Parsons
et al., 2011), suggesting that the resulting fusion gene may play
a crucial role in the respective tumor.
Characterization of the Molecular Nature of the
Catastrophic DNA Rearrangements with
Complementary Computational Approaches
To further characterize these complex rearrangements we
examined the visually apparent genomic clustering of amplified
regions, which were frequently found on single chromosome
arms, using computational simulations. We observed that
segments contributing to interconnected and highly amplified
(>10-fold change in copy number) loci displayed pronounced
topological clustering in all four sequenced SHH-MBs (Fig-
ure 5A), consistent with previous reports in the context of chro-
mothripsis (Stephens et al., 2011).
Simulations were also used to evaluate the possibility that
the observed patterns of vastly alternating normal disomicand ‘‘extreme’’ (highly amplified) copy-number states may be
explained by progressive rearrangements. We analyzed chro-
mosomes with inferred chromothripsis using 1,000 simulations
each, by progressively, and randomly, introducing all detected
intersegmental-connections that involved highly amplified
regions into the respective patients’ germline background in a
stepwise fashion (see Experimental Procedures). In all four
cases, based on the results of the simulations, a progressive
rearrangement model was rejected, thereby implicating the
occurrence of chromothripsis. In each case the simulations
resulted in less pronounced as well as less regular switches
between copy-number states than the actual data (p < 0.005;
based on permutations; Figure 5B).
Analysis of breakpoint sequence signatures (Lam et al., 2010)
revealed short microhomology tracts (%4 bp), compatible with
nonhomologous end-joining (NHEJ)-mediated double-strand
repair, or microhomology-mediated break-induced replication
(MMBIR) (Hastings et al., 2009a; Lee et al., 2007), for the vast
majority of breakpoints (Figure 5C). In a few cases, short
insertions of nontemplate DNA sequence were observed at the
breakpoint junctions (Table S5). NHEJ-mediated repair of shat-
tered DNA fragments appears more likely to be involved in this
context, as it is difficult to reconcile the model of MMBIR with
the massive rearrangements (including complex double-minute
chromosomes) we detected in association with chromothripsis.
Furthermore, we did not identify templated insertions—
commonly observed in association with replication-basedCell 148, 59–71, January 20, 2012 ª2012 Elsevier Inc. 65
Table 2. Chromothripsis-Associated Amplified Regions Typically
Contain Medulloblastoma Oncogenes
Chr Name Pathway/Process Sample Sources
4 ADAM29 Axonal Guidance
Signaling
LFS-MB1 (1)
3 BOC Sonic Hedgehog (SHH)
signaling pathway
LFS-MB1 (2)
7 CDK6 Cell cycle: G1/S
check point
LFS-MB2 (3)
2 GLI2 SHH signaling pathway LFS-MB4 (2, 3)
15 IGF1R Insulin-like growth
factor 1 signaling
LFS-MB3 (3)
2 MYCN MAPK- and SHH
signaling pathway
LFS-MB4 (2, 3)
3 NEK11 intra-S DNA damage
checkpoint
LFS-MB1 (3)
7 NAMPT * Nicotinate and
Nicotinamide Metabolism
LFS-MB2 (3)
2 NEB ** Striated Muscle
Contraction
LFS-MB4 (1)
Shown are oncogenes in highly amplified genomic regions (>10-fold
increased copy number) occurring in association with chromothripsis in
SHH-MB. Sources: (1) Parsons et al. (2011); (2) SHH signaling pathway
(manually curated); (3) cancer gene set curated by the Cancer Genome
Atlas (The Cancer Genome Atlas Research Network, 2008). *NAMPT is
C terminally fused to CDK6. **NEB is N terminally fused to ACTR3. Chr,
chromosome.rearrangement mechanisms (such as MMBIR)—at the break-
point junctions of chromothripsis-associated rearrangements.
TP53 Mutation Is Linked to Chromothripsis in Acute
Myeloid Leukemia
To investigate a potential association between TP53 mutations
and chromothripsis in LFS-associated tumors other than
medulloblastoma, we collected copy-number profile data for
tumors from eleven LFS patients (Extended Experimental
Procedures), including adrenocortical carcinoma (n = 4), rhab-
domyosarcoma (n = 4), extrarenal rhabdoid tumor (n = 1),
neuroblastoma (n = 1), and glioblastoma (n = 1). In all eleven
patients, DNA sequencing identified the presence of a TP53
mutation in the germline. Four out of the eleven (36%) tumors
showed rearrangements consistent with chromothripsis (Table
S2 and Data S1). While larger sample sizes of these rare tumor
entities are required for formal testing, our results indicate that
TP53 germline mutations could be linked with a high incidence
of chromothripsis in LFS-associated malignancies other than
medulloblastoma.
The occurrence of chromothripsis in an SHH-MBwith somatic
TP53mutation led us to further investigate relationships between
p53 and chromothripsis in other malignancies with available
high-resolution SNP microarray and somatic TP53 status. We
obtained such data for acute myeloid leukemia (AML) (Parkin
et al., 2010). Previous studies have reported that mutations in
TP53 correlate with ‘‘complex’’ karyotypes in AML (Haferlach
et al., 2008). The TP53 mutations in the AML patient cohort
were somatically acquired as assessed using paired constitu-66 Cell 148, 59–71, January 20, 2012 ª2012 Elsevier Inc.tional DNA (Parkin et al., 2010). Copy-number profiling revealed
an abundance of massive, complex rearrangements in the
TP53 mutated AMLs, with numerous alternating copy-number
state switches involving two or three copy-number states, that
were specifically localized to single chromosomes (Figure 5D,
Table S5). These rearrangements were markedly different from
the pattern of general genomic instability observed in proto-
typical TP53mutated tumors (Data S2), and implicated chromo-
thripsis in the tumorigenesis of TP53 mutated AMLs. In total,
8/17 (47%) AMLswith a somatically acquired TP53mutant geno-
type, but only 1/91 (1%) AMLs with wild-type TP53 (TP53+/+),
displayed patterns of rearrangement consistent with chromo-
thripsis, a finding that links somatic TP53mutationswith chromo-
thripsis in AML (p = 5.7 3 107; Fisher’s exact test).
We further analyzed a previously unpublished SNP microarray
dataset from a cohort of 311 AML patients with available karyo-
typic subgrouping. These included 56 ‘‘complex’’ karyotype
AMLs (Haferlach et al., 2008), 46% of which harbored TP53
mutations, and an additional 18% of which harbored a
TP53+/ genotype. Our analysis revealed a similar abundance
of chromothripsis among TP53 mutated tumors as in the
aforementioned AML cohort. When applying our strict definition
for inferring chromothripsis, approximately half of the TP53
mutated tumors showed chromothripsis (Data S2, Table S5),
while none of the cases classified as ‘‘noncomplex’’ karyotype
AML, which exhibit TP53 mutations in only 2% of cases
(Haferlach et al., 2008), harbored alterations resulting from
chromothripsis. An additional 12% of TP53 mutated AMLs
harbored rearrangements reminiscent of chromothripsis that
fell just below our conservative scoring threshold (Extended
Experimental Procedures).
We additionally tested for enrichment of cancer-related
genes in regions rearranged by chromothripsis in AML. In
contrast to SHH-MBs, the AML samples did not harbor high-
level amplifications in association with chromothripsis, and
instead showed hemizygous deletions of tumor suppressors
(Figure 5E), some of which have known roles in AML, including
FHIT, NBN, and IRF1 (Table S5). Further analysis of gene
expression profiles in these AML samples (Extended Experi-
mental Procedures), including cases with and without evidence
for chromothripsis, did not reveal evidence for SHH pathway
activation (Data S2), as was seen in TP53-mutated SHH-MBs
with chromothripsis. Thus, in AML chromothripsis is linked
with somatically acquired TP53 mutations, but not with SHH
pathway activation.
The availability of clinical follow-up data for the AML patients
also enabled us to test for an association of chromothripsis
with poor prognosis. We tested for such an association in both
aforementioned AML cohorts, controlling for patient age at
diagnosis, since AMLs harboring ‘‘complex’’ karyotypes display
an increased incidence in patients with advanced age (Mrozek,
2008). Indeed, we found that chromothripsis in AML is associ-
ated with poor survival (p < 0.0001; Wald’s test; Data S2),
an association that remained significant independent from
patient age, and ‘‘complex’’ karyotype classification, when
assessed in multivariate analyses. These tests also revealed an
increased age of diagnosis in TP53-mutated AMLs with chromo-
thripsis (median = 62 years (yr); mean = 67 yr), compared to
AC
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Figure 5. Analysis of Chromothripsis-Associated DNA Rearrangements in SHH-MB and AML
(A) Topographical clustering of amplified regions rearranged by chromothripsis. Sim., simulated amplicon distances (p values are based on 1,000 permutations).
(B) Simulations of progressive rearrangements segregate from the actual data in terms of mean excess in copy-number compared to unaffected regions.
(C) Rearrangement formation mechanisms analysis. Polymorphic genomic structural variants detected in the germline are shown for comparison. p values,
indicating significant differences between the distributions of inferred formation mechanisms, are based on Chi-square tests. VNTR, expansion or shrinkage
of regions with variable number of tandem repeats; MEI, mobile element insertions; NAHR, nonallelic homologous recombination (other abbreviations:
see main text).
(D) Somatically acquired TP53 mutations are linked with the occurrence of chromothripsis in AML. Black filled circles: AMLs with chromothripsis. Gray open
circles: AMLs without chromothripsis. Example copy-number profiles are available as Data S2, and a detailed summary of the AML data is in Table S5.
(E) Cancer gene enrichment in association with chromothripsis in SHH-MBs, analyzed by deep sequencing, and AMLs, analyzed by SNP arrays. Regions
hemizygously deleted (‘‘lost’’), gained, and highly (>10-fold) amplified as a consequence of chromothripsis were separately analyzed. No genes displayed
high-level amplification in AML in association with chromothripsis (NA). The asterisk indicates: significant based on Fisher’s exact test.TP53-mutated AMLs not showing chromothripsis (median =
57 yr; mean = 58 yr; p = 0.04; KS-test).
DISCUSSION
Integrated analysis of DNA sequencing and microarray data
enabled us to discover an association between mutations of
a specific gene, i.e., TP53, with chromothripsis. The unexpected
germline nature of mutant TP53 in several LFS-associated
SHH-MBs means that the TP53 mutation must precede themassive shattering and chromosome rearrangements in these.
This led us to propose a novel role for p53 in the initiation of,
or cellular reaction to, chromothripsis, with TP53 mutations
predisposing cells for chromothripsis, or facilitating cell survival
following catastrophic DNA rearrangements (Figure 6). The high
frequency of TP53 germline mutations specifically in SHH
tumors further suggests that LFS patients may be predisposed
to SHH-MB, rather than to medulloblastoma per se. This finding
has clinical implications, and we recommend assessing the
merit of testing SHH-MB patients with chromothripsis forCell 148, 59–71, January 20, 2012 ª2012 Elsevier Inc. 67
Figure 6. New Model Linking TP53Mutation Status to Catastrophic
DNA Rearrangements
Related references: 1Tabori et al. (2007); 2Tusell et al. (2010); 3Meyerson and
Pellman (2011); 4Vogelstein et al. (2000); 5Dahm-Daphi et al. (2005).germline TP53mutations, since regular screening in LFS families
was recently shown to lead to a survival benefit (Villani et al.,
2011). Additionally, particular care may be required with respect
to current treatment regimens, which in most cases include DNA
damaging agents and radiotherapy. These may induce therapy
resistance in the primary tumor or trigger secondary malignan-
cies in the context of constitutional TP53mutations and deficient
DNA repair.
The frequent occurrence of chromothripsis in the context of
germline alterations of TP53 points to a possible requirement
of TP53 mutations in the tumor cell-of-origin, or of TP53 muta-
tions acquired early in tumor development. The identification of
chromothripsis in the context of somatic TP53 mutations in an
SHH-MB patient and in several AMLs additionally implicates
acquired, tumor-specific TP53 mutations in chromothripsis.
Possible explanations for the absence of chromothripsis in
several malignancies with TP53 mutations, including several
AMLs and WNT medulloblastomas, are: their comparably late
acquisition of suchmutations; the occurrence of TP53mutations
in tumor subpopulations; and cell context-specific factors,
including distinct gene expression programs. Further to this,
selective growth advantages are likely to determine tumor devel-
opment following chromothripsis. The higher rate of chromo-
thripsis in TP53-mutated SHH-MBs (all cases we analyzed)
compared to TP53-mutated AMLs (approximately half of the
cases we analyzed) is striking. It is tempting to speculate that
this difference is connected with the abundance of high-level
oncogene amplifications, typically involving double-minute
chromosomes, in SHH-MBs with chromothripsis. The selective
advantage of such oncogene amplification is likely higher than
the selective advantage conferred by hemizygous tumor
suppressor gene loss observed in AML. Furthermore, rare cases
of chromothripsis in AMLs harboring wild-type TP53, and in68 Cell 148, 59–71, January 20, 2012 ª2012 Elsevier Inc.medulloblastomas with hemizygous TP53 deletion, show that
chromothripsis can also occur in the absence of TP53 point
mutations, perhaps in association with low TP53 gene dosage,
or other genetic or epigenetic mechanisms causing p53 pathway
dysregulation.
Our analyses of rearrangement breakpoints are in support of
a model of massive DNA double strand breaks (Stephens
et al., 2011), followed by NHEJ-mediated repair (Figure 6). The
replication-associated mechanism MMBIR can also generate
alterations with multiple breakpoints (Hastings et al., 2009a).
The lack of templated insertions at the breakpoint junctions,
however, which are thought to result from abortive attempts to
use another template during replication (Hastings et al., 2009b;
Howarth et al., 2011), does not substantiate the involvement of
a replication-associated rearrangement mechanism in the
complex alterations we observed.
Stephens et al. (2011) have discussed two possible scenarios
that may underlie the chromosome shattering and rearrange-
ment seen in chromothripsis. Both scenarios involve damage
occurring in mitotic chromosomes, since the compaction of
chromosomes during mitosis could explain the highly localized
nature of the DNA breaks, which are often focused on a single
chromosome. We note, however, that the known spatial organi-
zation of chromosomes maintained during interphase (Cremer
and Cremer, 2001; Lichter et al., 1988) might similarly represent
a structural basis for the local occurrence of DNA shattering. In
one scenario, it was proposed by Stephens et al. that ionizing
radiation may lead to a catastrophic series of DNA double strand
breaks. Based on our observations, these breaks might be
preferentially repaired by low-fidelity mechanisms, such as
error-prone NHEJ, as these are known to play a greater role
when levels of p53 activity are reduced (Dahm-Daphi et al.,
2005). An additional result of impaired p53 activity could be an
increased rate at which cells are able to survive, and divide, after
acquiring catastrophic chromosome alterations.
In a second possible scenario, critical telomere shortening
followed by chromosome end-to-end fusions (which are prone
to occur in association with uncapped telomeres [Tusell et al.,
2010]) and subsequent breakage could lead to chromothripsis.
Furthermore, dividing cells with uncapped telomeres are de-
layed at the G2/M transition in a p53-dependent manner, and
unprotected telomeres in p53-deficient cells undergoing mitosis
were found to be shorter than average, and prone to form end-
to-end fusions (Thanasoula et al., 2010). Intriguingly, LFS
patients harbor shortened telomeres compared to unaffected
individuals of the same age group, with average telomere length
decreasing from generation to generation in affected families,
and the age of onset of cancer showing an association with
average telomere length (Tabori et al., 2007; Trkova et al.,
2007). As two different chromosomes may participate in an
end-to-end fusion, such events could explain our observations
of chromothripsis leading to complex interchromosomal rear-
rangements (with derived double-minute chromosomes), which
involved nomore than two chromosomes. Thus, critical telomere
shortening followed by end-to-end fusions and subsequent
tearing apart during mitosis provides a plausible explanation
for the link between TP53 mutations and chromothripsis re-
ported in this study. The finding that chromothripsis frequently
occurred in individuals with advanced age at diagnosis in TP53
mutant AML is also of note, given the progressive shortening
of telomeres with age.
Additional contributions of p53 in controlling the G2/M transi-
tion checkpoint (Kastan and Bartek, 2004) suggest that the
involvement of a different mechanism—premature chromosome
compaction—may also be a possibility. In this process chromo-
somes from an S-phase nucleus condense prematurely and, as
a result, may become shattered (Meyerson and Pellman, 2011).
Given the multiple and varied roles that have been assigned to
p53 it is possible that the link between TP53 and chromothripsis
is associated with more than one of the aforementioned func-
tions acting in concert (Figure 6).
In contrast to earlier reports on the rarity of chromothripsis
(Kloosterman et al., 2011; Stephens et al., 2011), we found that
in specific biological contexts this phenomenon occurs at high
frequency. In conclusion, results from our study, which reported
the first whole-genome sequence data for tumors from LFS
patients and for pediatric brain tumors, indicate a new role for
p53, a protein also known as the ‘‘guardian of the genome.’’
Results from upcoming large-scale cancer genome sequencing
studies (The International Cancer Genome Consortium, 2010)
may shed light on additional factors associated with this cata-
strophic genomic phenotype.
EXPERIMENTAL PROCEDURES
Patients
Informed consent and an ethical vote (Institutional Review Board) were ob-
tained according to ICGC guidelines (www.icgc.org). No patient underwent
chemotherapy or radiotherapy prior to the surgical removal of the primary
tumor.
DNA Library Preparation and Sequencing
DNA library preparation was carried out using Illumina, Inc., paired-end (PE)
and mate-pair (MP, or long-range paired-end mapping) protocols. In brief,
5ug (PE) or 10ug (MP) of genomic DNA isolations were fragmented to
300 bp (PE) insert-size with a Covaris device, or to 4kb (MP) with a Hydro-
shear device, followed by size selection through agarose gel excision. Deep
sequencing was carried out with Genome Analyzer IIx and HiSeq2000 instru-
ments. Exome capturing was carried out with Agilent SureSelect Human All
Exon 50 Mb in-solution capture reagents (vendor’s protocol v2.0.1).
Sequence Variant Discovery and Analysis
We mapped DNA read data onto the human reference genome and sub-
sequently detected SNVs, InDels, and genomic rearrangements with
complementary computational approaches (see Extended Experimental
Procedures).
SNP Arrays
SNP arrays were hybridized, and copy-number alterations identified, as previ-
ously described (Northcott et al., 2009). We inferred chromothripsis in cases
where at least ten switches between two or three copy-number states were
apparent on an individual chromosome, e.g., a sequence of the states ‘20
and ‘1’ (‘2; 1; 2; 1; 2; 1; 2; 1; 2; 1; 20), or ten switches between ‘20 and a highly
amplified (e.g., ‘‘30’) state (‘2; 30; 2; 30; 2; 30; 2; 30; 2; 30; 20). We chose this
threshold as we and others have demonstrated that whereas sporadic medul-
loblastomas display a high degree of variability in the level of observed copy
number alterations, specific patterns of alternating copy-number patterns
with multiple breakpoints localized on one chromosome, involving few copy-
number states, have not previously been described in these (Cho et al.,
2011; Northcott et al., 2009; Pfister et al., 2009).PCR Validation
PCR validations for breakpoint junctions were performed as previously
described (Korbel et al., 2007). SNVs were validated by PCR, followed by
capillary sequencing in whole genome amplified (QIAGEN) DNA samples.
FISH
FISH was performed as previously described (Pfister et al., 2009).
Breakpoint Clustering Simulation
To evaluate topographical clustering of chromothripsis-associated DNA
segments we shuffled the location of amplicons (>10-fold change in copy
number) along single chromosomes, using 1,000 simulations each. We
limited our simulations to mappable regions of the reference genome (i.e.,
genomic segments where > 50% of the DNA reads could be uniquely
aligned).
Rearrangement Formation Mechanism Analysis
Rearrangement mechanisms were inferred with BreakSeq (Lam et al., 2010),
using recently described classification parameters (Mills et al., 2011).
Simulations of the Progressive Rearrangement Model
We simulated progressively occurring alterations based on a recently formu-
lated computational approach (Stephens et al., 2011), as described in detail
in the Extended Experimental Procedures.
Cancer Gene Enrichment Analysis
Lists of cancer-related genes associated with SHH-MB and AML were
compiled by supplementing a curated general cancer gene set with compre-
hensive lists of previously published disease-specific genes (see Table S5
and Extended Experimental Procedures). We then assessed whether these
gene sets were enriched in regions affected by chromothripsis compared to
the whole set of RefSeq genes, using Fisher’s exact test.ACCESSION NUMBERS
Sequence data analyzed in our study can be accessed from EGA (accession:
EGAS00001000085) and microarray data from GEO (accessions: GSE14437,
GSE32462, GSE19101, GSE23452, GSE34323, and GSE34258).SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, two
data files, five tables, and two figures and can be found with this article online
at doi:10.1016/j.cell.2011.12.013.
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